News

Press Releases

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the granting of a $3.0M award from the Medical Technology Enterprise Consortium (MTEC).  The MTEC project award will support the upcoming Phase 1 human safety studies of […]

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Astrocyte is developing AST-004, a potential therapy for traumatic […]

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations

Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today that Lisa Manna has joined Astrocyte as the Vice-President of Clinical Development Operations.  Ms. Manna brings extensive experience in clinical and development operations, working with contract research […]

Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of the Company’s Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004, based upon technology originally licensed from The University […]

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board (CAB) with leading stroke and traumatic brain injury (TBI) clinical experts.   The Board will be Chaired by current advisor Dr. Jeffrey L. Saver, and include ongoing advisor Dr. David W. […]

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating the efficacy of AST-004 in a non-human primate (NHP) model of stroke.  Dr. Theodore Liston, Vice President of Research at Astrocyte, presented the talk entitled, “Significant Efficacy […]

see all

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders